Clinical Trial Update: A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants [Phase 1]

View source ↗

Summary

AbbVie completed a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of ALIA-1758 in healthy participants for Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ALIA-1758

Snippet

Sponsor: AbbVie | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED